Cyclooxygenases and lipoxygenases in prostate and breast cancers

Frontiers in Bioscience

Volumn 12, Issue 4, 2007, Pages 1574-1585

  Nie, Daotai ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Apoptosis; Cyclooxygenase; Eicosanoid; Lipoxygenase; Tumor progression

Indexed keywords

EID: 34249791166     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2170     Document Type: Article

References (138)

1. Fleshner N, P. S. Bagnell, L. Klotz & V. Venkateswaran: Dietary fat and prostate cancer. J Urol 171, S19-24 (2004)
2. Funk C. D: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875 (2001)
3. Shinohara H, M. A. Balboa, C. A.Johnson, J. Balsinde & E. A. Dennis: Regulation of delayed prostaglandin production in activated P388D1 macrophages by group IV cytosolic and group V secretory phospholipase A2s. J Biol Chem 274, 12263-12268 (1999)
4. Hara S, A. Miyata, C. Yokoyama, H. Inoue, R. Brugger, F. Lottspeich, V. Ullrich & T. Tanabe: Isolation and molecular cloning of prostacyclin synthase from bovine endothelial cells. J Biol Chem 269, 19897-19903 (1994)
5. Kuwamoto S, H. Inoue, Y. Tone, Y. Izumi & T. Tanab: Inverse gene expression of prostacyclin and thromboxane synthases in resident and activated peritoneal macrophages. FEBS Lett 409, 242-246 (1997)
6. Suzuki T, K. Watanabe, Y. Kanaoka, T. Sato & O. Hayaishi: Induction of hematopoietic prostaglandin D synthase in human megakaryocytic cells by phorbol ester. Biochem Biophys Res Commun 241, 288-293 (1997)
7. Jakobsson PJ, S. Thoren, R. Morgenstern & B. Samuelsson: Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 96, 7220-7225 (1999)
8. Bonvalet JP, P. Pradelles & N. Farman: Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol 253, F377-387 (1987)
9. Smith WL: Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263, F181-191 (1992)
10. Narumiya S, Y. Sugimoto & F. Ushikubi: Prostanoid receptors: structures, properties, and functions. Physiol Rev 79, 1193-1226 (1999)
11. Eberhart CE, R. J. Coffey, A. Radhika, F. M. Giardiello, S. Ferrenbach & R. N.DuBois: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188 (1994)
12. DuBois RN, A. Radhika, B. S. Reddy & A. J Entingh: Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110, 1259-1262 (1996)
13. Molina MA, M. Sitja-Amau, M. G. Lemoine, M. L. Frazier & F. A. Sinicrope: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59, 4356-4362 (1999)
14. Tucker ON, A. J. Dannenberg, E. K. Yang, F. Zhang, L. Teng, J. M. Daly, R. A. Soslow, J. L. Masferrer, B. M. Woerner, A. T. Koki & T. J. Fahey: 3rd Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59, 987-990 (1999)
15. Dubinett SM, S. Sharma, M. Huang, M. Dohadwala, M. Pold & J. T. Mao: Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res 37, 138-162 (2003)
16. Achiwa H, Y. Yatabe, T. Hida, T. Kuroishi, K. Kozaki, S. Nakamura, M. Ogawa, T. Sugiura, T. Mitsudomi & T. Takahashi: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5, 1001-1005 (1999)
17. Hida T, Y. Yatabe, H. Achiwa, H. Muramatsu, K. Kozaki, S. Nakamura, M. Ogawa, T. Mitsudomi, T. Sugiura & T. Takahashi: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58, 3761-3764 (1998)
18. Takahashi T, K. Kozaki, Y. Yatabe, H. Achiwa & T. Hida: Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol, 21, 177-181 (2002)
19. Uefuji K, T. Ichikura, H. Mochizuki & N. Shinomiya: Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 69, 168-172 (1998)
20. Uefuji K, T. Ichikura & H. Mochizuki: Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 76, 26-30 (2001)
21. Soydan AS, J. D. Gaffen, P. K. Weech, N. M. Tremblay, S. Kargman, G. O'Neill, A. Bennett & I. A. Tavares: Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours. Eur J Cancer 33, 1508-1512 (1997)
22. Kundu N, Q. Yang, R.Dorsey & A. M. Fulto: Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 93, 681-686 (2001)
23. Barnes N, P. Haywood, P. Flint, W. F. Knox & N. J. Bundred: Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 94, 253-258 (2006)
24. Tang DW, S. C. Lin, K. W. Chang, C. W. Chi, C. S. Chang & T. Y. Liu: Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma-evidence for COX-2 induction by areca quid ingredients in oral keratinocytes. J Oral Pathol Med 32, 522-529 (2003)
25. Zimmermann KC, M. Sarbia, A. A. Weber, F. Borchard, H. E. Gabbert & K. Schror: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59, 198-204 (1999)
26. Lee LM, C. C. Pan, C. J. Cheng, C. W. Chi & T. Y. Liu: Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 21, 1291-1294 (2001)
27. Kirschenbaum A, A. P. Klausner, R. Lee, P. Unger, S. Yao, X. H. Liu & A. C. Levine: Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56, 671-676 (2000)
28. Kirschenbaum A, D. R. Liotta, S. Yao, X. H. Liu, A. P. Klausner, P. Unger, E. Shapiro, I. Leav & A. C. Levine: Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts. J Clin Endocrinol Metab 85, 3436-3441 (2000)
29. Kandil HM, G. Tanner, W. Smalley, S. Halter, A. Radhika & R. N. Dubois: Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 46, 785-789 (2001)
30. Hasegawa K, Y. Ohashi, K. Ishikawa, A. Yasue, R. Kato, Y. Achiwa, E. Nishio & Y. Udagawa: Expression of cyclooxygenase-2 in uterine endometrial cancer and antitumor effects of a selective COX-2 inhibitor. Int J Oncol, 26, 1419-1428 (2005)
31. Sheng H, C. S. Williams, J. Shao, P. Liang, R. N. DuBois & R. D. Beauchamp: Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem 273, 22120-22127 (1998)
32. Subbaramaiah K, N. Altorki, W. J. Chung, J. R. Mestre, A. Sampat & A. Dannenber: J. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274, 10911-10915 (1999)
33. Gupta RA, L. V. Tejada, B. J. Tong, S. K. Das, J. D. Morrow, S. K. Dey& R. N. DuBois: Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 63, 906-911 (2003)
34. Sheng H, J. Shao, S. C. Kirkland, P. Isakson, R. J. Coffey, J. Morrow, R. D. Beauchamp & R. N. DuBois: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99, 2254-2259 (1997)
35. Sheng GG, J. Shao, H. Sheng, E. B. Hooton, P. C. Isakson, J. D. Morrow, R. J. Jr. Coffey, R. N. DuBois & R. D. Beauchamp: A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 113, 1883-1891 (1997)
36. Sheng H, J. Shao, J. D. Morrow, R. D. Beauchamp & R. N. DuBois: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58, 362-366 (1998)
37. Liu XH, S. Yao, A. Kirschenbaum & A. C. Levine: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58, 4245-4249 (1998)
38. Shiff SJ, L. Qiao, L. L. Tsai & B. Rigas: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96, 491-503 (1995)
39. Thun MJ, S. J. Henley & C. Patrono: Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266 (2002)
40. Oshima M, J. E. Dinchuk, S. L. Kargman, H. Oshima, B. Hancock, E. Kwong, J. M. Trzaskos, J. F. Evans & M. M. Taketo: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803-809 (1996)
41. Kirkpatrick K, W. Ogunkolade, A. Elkak, S. Bustin, P. Jenkins, M. Ghilchik & K. Mokbe: The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 18, 237-241 (2002)
42. Gallo O, A. Franchi, L. Magnelli, I. Sardi, A. Vannacci, V. Boddi, V. Chiarugi & E. Masini: Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3, 53-61 (2001)
43. Tsujii M, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori & R. N. DuBois: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705-716 (1998)
44. Sawaoka H, S. Tsuji, M. Tsujii, E. S. Gunawan, Y. Sasaki, S. Kawano & M. Hori: Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 79, 1469-1477 (1999)
45. Liu XH, A. Kirschenbaum, S. Yao, R. Lee, J. F. Holland & A. C. Levine: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164, 820-825 (2000)
46. Liu XH., A. Kirschenbaum, S. Yao, M. E. Stearns, J. F. Holland, K. Claffey & A. C. Levine: Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 17, 687-694 (1999)
47. Huang SP, M. S. Wu, C. T. Shun, H. P. Wang, C. Y. Hsieh, M. L. Kuo & J. T. Lin: Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci 12, 229-241 (2005).
48. Pai R, I. L. Szabo, B. A. Soreghan, S. Atay, H. Kawanaka & A. S. Tarnawski: PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 286, 923-928 (2001)
49. Tsujii M, S. Kawano & R. N. DuBois: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94, 3336-3340 (1997)
50. Attiga FA, P. M. Fernandez, A. T. Weeraratna, M. J. Manyak & S. R. Patierno: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60, 4629-4637 (2000)
51. Ratliff TL: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). J Urol 174, 787-788 (2005)
52. Takeuchi K, A. Tanaka, Y. Hayashi & A. Yokota: COX inhibition and NSAID-induced gastric damage - roles in various pathogenic events. Curr Top Med Chem 5, 475-486 (2005)
53. Wang D & R. N. Dubois: Prostaglandins and cancer Gut (2005)
54. Lenzer J: FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. Bmj 330: 440 (2005)
55. Wang D & R. N. DuBois: Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A 101, 415-416 (2004)
56. Chang SH, C. H. Liu, R. Conway, D. K. Han, K. Nithipatikom, O. C. Trifan, T. F. Lane & T. Hla: Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 101, 591-596 (2004)
57. Nie D, M. Che, A. Zacharek, Y. Qiao, L. Li, X. Li, M. Lamberti, K. Tang, Y. Cai, Y. Guo, D. Grignon & K. V. Honn: Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol 164, 429-439 (2004)
58. Chen GG, T. W. Lee, J. H. Yip, H. Xu, I. K. Lee, T. S. Mok, T. D. Warner & A. P. Yim: Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. Cancer Lett (2005)
59. Kajita S, K. H. Ruebel, M. B. Casey, N. Nakamura & R. V. Lloyd: Role of COX-2, thromboxane A2 synthase, and prostaglandin 12 synthase in papillary thyroid carcinoma growth. Mod Pathol 18, 221-227 (2005)
60. Pinto S, L. Gori, O. Gallo, S. Boccuzzi, R. Paniccia & R. Abbate: Increased thromboxane A2 production at primary tumor site in metastasizing squamous cell carcinoma of the larynx. Prostaglandins Leukot Essent Fatty Acids 49, 527-530 (1993)
61. Bryant J: Correlation .between metastatic patterns in renal cell carcinoma and tissue distribution of thromboxane synthetase. Acta Oncol 33, 708-709 (1994)
62. Giese A, C. Hagel, E. L. Kim, S. Zapf, J. Djawaheri, M. E. Berens & M. Westphal: Thromboxane synthase regulates the migratory phenotype of human glioma cells. Neuro-oncol 1, 3-13 (1999)
63. McDonough W, N. Tran, A. Giese, S. A. Norman & M. E. Berens: Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase. J Neuropathol Exp Neural 57, 449-455 (1998)
64. Rodrigues S, Q. D. Nguyen, S. Faivre, E. Bruyneel, L. Thim, B. Westley, F. May, G. Flatau, M. Mareel, C. Gespach & S. Emami: Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. Faseb J 15, 1517-1528 (2001)
65. Nie D, M. Che, D. Grignon, K. Tang & K. V. Honn: Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev 20, 195-206 (2001)
66. Jiang WG, A. G. Douglas-Jones & R. E. Mansel: Aberrant expression of Slipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot Essent Fatty Acids 74, 125-134 (2006)
67. Li N, S. Sood, S. Wang, M. Fang, P. Wang, Z. Sun, C. S. Yang & X. Chen Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res, 11, 2089-2096 (2005)
68. Hoque A, S. M. Lippman, T. T. Wu, Y. Xu, Z. D. Liang, S. Swisher, H. Zhang, L. Cao, J. A. Ajani & X. C. Xu: Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 26, 785-791 (2005)
69. Nielsen CK, J. F. Ohd, K. Wikstrom, R. Massoumi, S. Paruchuri, M. Juhas & A. Sjolander: The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer. Adv Exp Med Biol 525, 201-204 (2003)
70. Gupta S, M. Srivastava, N. Ahmad, K. Sakamoto, D. G. Bostwick & H. Mukhtar: Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91, 737-743 (2001)
71. Wu X, S. S. Biswal & J. P. Kehrer: Roles of 5-lipoxygenase activating protein in cell proliferation and apoptosis. Cell Biol Toxicol 19, 135-143 (2003)
72. Anderson KM, T. Seed, M. Vos, J. Mulshine, J. Meng, W. Alrefai, D. Ou & J. E. Harris: 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 37, 161-173 (1998)
73. Ghosh J & C. E. Myers: Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A 95, 13182-13187 (1998)
74. Matsuyama M, R. Yoshimura, M. Mitsuhashi, K. Tsuchida, Y. Takemoto, Y. Kawahito, H. Sano & T. Nakatani: 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep 14, 73-79 (2005)
75. Fan XM, S. P. Tu, S. K. Lam, W. P. Wang, J. Wu, W. M. Wong, M. F. Yuen, M. C. Lin, H. F. Kung & B. C. Wong: Five-lipoxygenase-activating protein inhibitor MK886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax. J Gastroenterol Hepatol 19, 31-37 (2004)
76. Tong WG, X. Z. Ding, R. C. Witt, & T. E. Adrian: Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 1, 929-935 (2002)
77. Tong WG, X. Z. Ding & T. E. Adrian: The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun 296, 942-948 (2002)
78. Avis I, S. H. Hong, A. Martinez, T. Moody, Y. H. Choi, J. Trepel, R. Das, M. Jett & J. L. Mulshine: Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. Faseb J 15, 2007-2009 (2001)
79. Ghosh J: Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem Biophys Res Commun 307, 342-349 (2003)
80. Sundaram S & J. Ghosh: Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochem Biophys Res Commun 339, 93-98 (2006)
81. Catalano A, P. Caprari, S. Soddu, A. Procopio & M. Romano: 5-lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking. Faseb J 18, 1740-1742 (2004)
82. Honn KV, D.G. Tang, X. Gao, I.A. Butovich, B. Liu, J. Timar & W. Hagmann: 12-lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev 13, 365-396 (1994)
83. Hagmann W, X. Gao, J. Timar, Y. Q. Chen, A. R. Strohmaier, C. Fahrenkopf, D. Kagawa, M. Lee, A. Zacharek & K. V. Honn: 12-Lipoxygenase in A431 cells: genetic identity, modulation of expression, and intracellular localization. Exp Cell Res 228, 197-205 (1996)
84. Hagmann W, X. Gao, A. Zacharek, L. A. Wojciechowski & K. V. Honn: 12-Lipoxygenase in Lewis lung carcinoma cells: molecular identity, intracellular distribution of activity and protein, and Ca(2+)-dependent translocation from cytosol to membranes. Prostaglandins 49, 49-62 (1995)
85. Chen YQ, Z. M. Duniec, B. Liu, W. Hagmann, X. Gao, K. Shimoji, L. J. Marnett, C. R. Johnson & K. V. Honn: Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res 54, 1574-1579 (1994)
86. Silletti S, J. Timar, K. V. Honn & A. Raz: Autocrine motility factor induces differential 12-lipoxygenase expression and activity in high- and low-metastatic K1735 melanoma cell variants. Cancer Res 54, 5752-5756 (1994)
87. Gao X, D. J. Grignon, T. Chbihi, A. Zacharek, Y. Q. Chen, W. Sakr, A. T. Porter, J. D. Crissman, J. E. Pontes, I. J. Powell & et al: Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 46, 227-237 (1995)
88. Connolly JM & D. P. Rose: Enhanced angiogenesis and growth of 12-lipoxygenase gene-transfected MCF-7 human breast cancer cells in athymic nude mice. Cancer Lett 132, 107-112 (1998)
89. Nie D, G. G. Hillman, T. Geddes, K. Tang, C. Pierson, D. J. Grignon & K. V. Honn: Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 58, 4047-4051 (1998)
90. Nie D, K. Tang, C. Diglio & K. V. Honn: Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood 95, 2304-2311 (2000)
91. Tang DG, Y. Q. Chen & K. V. Honn: Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci U S A 93, 5241-5246 (1996)
92. Ding XZ, C. A. Kuszynski, T. H. El-Metwally & T. E. Adrian: Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Commun 266, 392-399 (1999)
93. Wong BC, W. P. Wang, C. H. Cho, X. M. Fan, M. C. Lin, H. F. Kung & S. K. Lam: 12-Lipoxygenase inhibition induced apoptosis in human gastric cancer cells. Carcinogenesis 22, 1349-1354 (2001)
94. Pidgeon GP, M. Kandouz, A. Meram & K. V. Honn: Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res 62, 2721-2727 (2002)
95. Lebeau A, F. Terro, W. Rostene & D. Pelaprat: Blockade of 12-lipoxygenase expression protects cortical neurons from apoptosis induced by beta-amyloid peptide. Cell Death Differ 11, 875-884 (2004)
96. Zhang Y, H. Wang, J. Li, D. A. Jimenez, E. S. Levitan, E. Aizenman & P. A. Rosenberg: Peroxynitrite-induced neuronal apoptosis is mediated by intracellular zinc release and 12-lipoxygenase activation. J Neurosci 24, 10616-10627 (2004)
97. Lovat PE, S. Oliverio, M. Ranalli, M. Corazzari, C. Rodolfo, F. Bernassola, K. Aughton, M. Maccarrone, Q. D. Hewson, A. D. Pearson, G. Melino, M. Piacentini & C. P. Redfern: GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Res 62, 5158-5167 (2002)
98. Gu J, Y. Liu, Y. Wen, R. Natarajan, L. Lanting & J. L. Nadler: Evidence that increased 12-lipoxygenase activity induces apoptosis in fibroblasts. J Cell Physiol 186, 357-365 (2001)
99. Nie D, J. Nemeth, Y. Qiao, A. Zacharek, L. Li, K. Hanna, K. Tang, G. G. Hillman, M. L. Cher, D. J. Grignon & K. V. Honn: Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clin Exp Metastasis 20, 657-663 (2003).
100. Tang DG, J. Timar, I. M. Grossi, C. Renaud, V. A. Kimler, C. A. Diglio, J. D. Taylor & K. V. Honn: The lipoxygenase metabolite, 12(S)-HETE, induces a protein kinase C-dependent cytoskeletal rearrangement and retraction of microvascular endothelial cells. Exp Cell Res 207, 361-375 (1993)
101. Timar J, S. Silletti, R. Bazaz, A. Raz & K. V. Honn: Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-HETE. Int J Cancer 55, 1003-1010 (1993)
102. Honn KV, J. Timar, J. Rozhin, R. Bazaz, M. Sameni, G. Ziegler & B. F. Sloane: A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells. Exp Cell Res 214, 120-130 (1994)
103. Timar J, R. Bazaz, V. Kimler, M. Haddad, D. G. Tang, D. Robertson, J. Tovari, J. D. Taylor & K. V. Honn: Immunomorphological characterization and effects of 12-(S)-HETE on a dynamic intracellular pool of the alpha IIb beta 3-integrin in melanoma cells. J Cell Sci 108 (Pt 6), 2175-2186 (1995)
104. Liu B, J. Timar, J. Hewlett, C. A. Diglio & K. V. Honn: Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C. Cell Regul 2,1045-1055 (1991)
105. Liu B, R. J. Maher, Y. A. Hannun, A. T. Porter & K. V. Honn: 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. J Natl Cancer Inst 86, 1145-1151 (1994)
106. Spindler SA, F. H. Sarkar, W. A. Sakr, M. L. Blackburn, A. W. Bull, M. LaGattuta & R. G. Reddy: Production of 13-hydroxyoctadecadienoic acid (13-HODE) by prostate tumors and cell lines. Biochem Biophys Res Commun 239, 775-781 (1997)
107. Kelavkar UP, C. Cohen, H. Kamitani, T. E. Eling & K. F. Badr: Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis 21, 1777-1787 (2000)
108. Shureiqi I, Y. Wu, D. Chen, X. L. Yang, B. Guan, J. S. Morris, P. Yang, R. A. Newman, R. Broaddus, S. R. Hamilton, P. Lynch, B. Levin, S. M. Fischer & S. M. Lippman: The Critical Role of 15-Lipoxygenase-1 in Colorectal Epithelial Cell Terminal Differentiation and Tumorigenesis. Cancer Res 65, 11486-11492 (2005)
109. Shureiqi I, K. J. Wojno, J. A. Poore, R. G. Reddy, M. J. Moussalli, S. A. Spindler, J. K. Greenson, D. Normolle, A. A. Hasan, T. S. Lawrence & D. E. Brenner: Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 20, 1985-1995 (1999)
110. Kamitani H, S. Taniura, H. Ikawa, T. Watanabe, U. P. Kelavkar & T. E. Eling: Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma. Carcinogenesis 22, 187-191 (2001)
111. Liu C, D. Xu, J. Sjoberg, P. Forsell, M. Bjorkholm & H. E. Claesson: Transcriptional regulation of 15-lipoxygenase expression by promoter methylation. Exp Cell Res 297, 61-67 (2004)
112. Shappell SB, S. J. Olson, S. E. Hannah, S. Manning, R. L. Roberts, N. Masumori, M. Jisaka, W. E. Boeglin, V. Vader, D. S. Dave, M. F. Shook, T. Z. Thomas, C. D. Funk, A. R. Brash & R. J. Matusik: Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res 63, 2256-2267 (2003)
113. Kelavkar UP, W. Glasgow, S. J. Olson, B. A. Foster & S. B. Shappell: Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia 6, 821-830 (2004)
114. Kelavkar UP, J. B. Nixon, C. Cohen, D. Dillehay, T. E. Eling & K. F. Badr: Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 22, 1765-1773 (2001)
115. Kelavkar UP & C. Cohen: 15-lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells. Neoplasia 6, 41-52 (2004)
116. Shureiqi I, X. Xu, D. Chen, R. Lotan, J. S. Morris, S. M. Fischer & S. M. Lippman: Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res 61, 4879-4884 (2001)
117. Shureiqi I, W. Jiang, S. M. Fischer, X. Xu, D. Chen, J. J. Lee, R. Lotan & S. M. Lippman: GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res 62, 1178-1183 (2002)
118. Kamitani H, H. Kameda, U. P. Kelavkar & T. E. Eling: A GATA binding site is involved in the regulation of 15-lipoxygenase-1expression in human colorectal carcinoma cell line, caco-2. FEBS Lett 467, 341-347 (2000)
119. Kamitani H, M. Geller & T. Eling: Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J Biol Chem 273, 21569-21577 (1998)
120. Nixon JB, K. S. Kim, P. W. Lamb, F. G. Bottone & T. E. Eling: 15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer. Prostaglandins Leukot Essent Fatty Acids 70, 7-15 (2004)
121. Shureiqi I, W. Jiang, X. Zuo, Y. Wu, J. B. Stimmel, L. M. Leesnitzer, J. S. Morris, H. Z. Fan, S. M. Fischer & S. M. Lippman: The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 100, 9968-9973 (2003)
122. Kim JS, S. J. Baek, F. G. Jr. Bottone, T. Sali & T. E. Eling: Overexpression of 15-lipoxygenase-1 induces growth arrest through phosphorylation of p53 in human colorectal cancer cells. Mol Cancer Res 3, 511-517 (2005)
123. Brash AR, W. E. Boeglin & M. S. Chang: Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci U S A 94, 6148-6152 (1997)
124. Chang MS, C. Schneider, R. L. Roberts, S. B. Shappell, F. R. Haselton, W. E. Boeglin & A. R. Brash: Detection and subcellular localization of two 15S-lipoxygenases in human cornea. Invest Ophthalmol Vis Sci 46, 849-856 (2005)
125. Shappell SB, W. E. Boeglin, S. J. Olson, S. Kasper & A. R. Brash: 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 155, 235-245 (1999)
126. Shappell SB, D. S. Keeney, J. Zhang, R. Page, S. J. Olson & A. R. Brash: 15-Lipoxygenase-2 expression in benign and neoplastic sebaceous glands and other cutaneous adnexa. J Invest Dermatol 117, 36-43 (2001)
127. Jack GS, A. R. Brash, S. J. Olson, S. Manning, C. S. Coffey, J. A. Jr. Smith & S. B. Shappell: Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 31, 1146-1154 (2000)
128. Gonzalez AL, R. L. Roberts, P. P. Massion, S. J. Olson, Y. Shyr & S. B. Shappell: 15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation. Hum Pathol 35, 840-849 (2004)
129. Xu XC, S. B. Shappell, Z. Liang, S. Song, D. Menter, V. Subbarayan, S. Iyengar, D. G. Tang & S. M. Lippman: Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 5, 121-127 (2003)
130. Tang S, B. Bhatia, C. J. Maldonado, P. Yang, R. A. Newman, J. Liu, D. Chandra, J. Traag, R. D. Klein, S. M. Fischer, D. Chopra, J. Shen, H. E. Zhau, L. W. Chung & D. G. Tang: Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 277, 16189-16201 (2002)
131. Tang S, B. Bhatia, J. Zhou, C. J. Maldonado, D. Chandra, E. Kim, S. M. Fischer, A. P. Butler, S. L. Friedman & D. G. Tang: Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells. Oncogene 23, 6942-6953 (2004)
132. Bhatia B, S. Tang, P. Yang, A. Doll, G. Aumueller, R. A. Newman & D. G. Tang: Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells. Oncogene 24, 3583-3595 (2005)
133. Bhatia B, C. J. Maldonado, S. Tang, D. Chandra, R. D. Klein, D. Chopra, S. B. Shappell, P. Yang, R. A. Newman & D. G. Tang: Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J Biol Chem 278, 25091-25100 (2003)
134. Forman BM, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman & R. M. Evans: 15-Deoxy -delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83, 803-812 (1995)
135. Shappell SB, R. A. Gupta, S. Manning, R. Whitehead, W. E. Boeglin, C. Schneider, T. Case, J. Price, G. S. Jack, T. M. Wheeler, R. J. Matusik, A. R. Brash & R. N. Dubois: 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 61, 497-503 (2001)
136. Pham H, T. Banerjee, G. M. Nalbandian & V. A. Ziboh: Activation of peroxisome proliferator-activated receptor (PPAR)-gamma by 15S- hydroxyeicosatrienoic acid parallels growth suppression of androgen-dependent prostatic adenocarcinoma cells. Cancer Lett 189, 17-25 (2003)
137. Subbarayan V, X. C. Xu, J. Kim, P. Yang, A. Hoque, A. L. Sabichi, N. Llansa, G. Mendoza, C. J. Logothetis, R. A. Newman, S. M. Lippman & D. G. Menter: Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7, 280-293 (2005)
138. Saez E, P. Olson & R. M. Evans: Genetic deficiency in Pparg does not alter development of experimental prostate cancer. Nat Med 9, 1265-1266 (2003)